TotalMarketCap

Beam Therapeutics

BEAMNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$2.680 B

$25.90 -6.82%

Close of 6 Nov 2026

As of 6 Nov 2026, Beam Therapeutics (BEAM) has a market capitalization of $2.68B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$139.7M

#2390 by revenue

Earnings

-$80.0M

Loss-making

Shares outstanding

103,495,644

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #28Denali TherapeuticsDNLI$3.16B
  2. #29Adma BiologicsADMA$2.94B
  3. #30Beam TherapeuticsBEAM$2.68B
  4. #31VericelVCEL$2.65B
  5. #32Recursion PharmaceuticalsRXRX$2.18B

What if Beam Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$272,831.52

Per share 10,536× higher

Bitcoin $1.53T

$14,762.44

Per share 570× higher

Apple $5.02T

$48,463.71

Per share 1,872× higher

Or at a round number

$5.00B$10.0B$20.0B$50.0B

Where these numbers come from

Share counts and financials for Beam Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.